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Matrix metalloproteinases (MMPs) and related enzymes (ADAMs, 
ADAMTS) and their inhibitors control matrix turnover and func-
tion. Recent advances in our understanding of musculoskeletal 
conditions such as tendinopathy, arthritis, Dupuytren’s disease, 
degenerative disc disease, and bone and soft tissue healing sug-
gest that MMPs have prominant roles. Importantly, MMPs are 
amenable to inhibition by cheap, safe, and widely available drugs 
such as the tetracycline antibiotics and the bisphosphonates. This 
indicates that these MMP inhibitors, if proven effective for any 
novel indication, may be quickly brought into clinical practice.  

Tissue-degrading  enzymes  of  the  metalloproteinase  family 
have been implicated in the pathogenesis of several condi-
tions involving the extracellular matrix. The family includes 
the matrix metalloproteinases (MMPs), their close relatives 
“a disintegrin and metalloproteinase” (ADAM), and “a dis-
integrin and metalloproteinase with thrombospondin motifs” 
(ADAMTS). MMPs are promising drug targets, and they are 
amenable to pharmacological inhibition by common clinically 
available  drugs  such  as  tetracyclines  and  bisphosphonates. 
A better understanding of the roles of metalloproteinases in 
tissue injury and the effects of their inhibition has the poten-
tial to improve outcome after injury and surgery. Addition- Addition-
ally, metalloproteinases have diagnostic potential as markers 
to predict outcome of disease processes and healing, and to 
direct tailored therapy. 
There has only been one published overview of the role of 
MMPs in orthopedics (Bramono et al. 2004), covering mostly 
arthritis. We extend the scope of that review by adding data 
from reports published in recent years and include a discus-
sion on the ADAMs and ADAMTS, as well as conditions such 
as tendinopathy, Dupuytren’s contracture, bone and soft tissue 
healing, and prosthetic loosening. 
Enzymes in control of the extracellular matrix
Matrix metalloproteinases and their endogenous inhibitors. 
Turnover of the extracellular matrix is a dynamic equilibrium 
between synthesis and degradation. Degradation is to a large 
extent mediated by matrix metalloproteinase (MMP) enzymes, 
which are antagonized by tissue inhibitors of metalloprotein-
ases (TIMPs). 
MMPs are a family of at least 24 zinc-dependent endopep-
tidases  capable  of  degrading  practically  all  components  of 
the extracellular matrix (Table 1). MMPs contribute to many 
physiological processes through modification of the extracel-
lular matrix (ECM) (Mandal et al. 2003). �ecent insights sug- �ecent insights sug-
gest that MMPs may also have a broader spectrum of func-
tions including regulation of the inflammatory response, for 
example through effects on chemokine and cytokine signal-
ing and by release of neoepitopes from the ECM (Pearce and 
Shively 2006). MMPs have been subdivided according to their 
main (or first discovered) degradative activity, and the list of 
known substrates is continously growing. The collagenases 
(MMP-1, -8, and -13) are able to degrade practically all sub-
types of collagen, most importantly the fibrillar collagens that 
provide mechanical strength to tissues. Collagenase 4 (MMP-
18) is classically described as a Xenopus collagenase and is 
often omitted from lists of human MMPs. However, detectable 
levels of m�NA for this enzyme have been found in human 
ligaments (Foos et al. 2001). In addition to the classical col- In addition to the classical col-
lagenases, MMP-2 and MMP-14 (see below) also have impor-
tant collagenolytic activity. 
The gelatinases (MMP-2 and -9) degrade smaller collagen 
fragments, released during activity of the collagenases. Mem-
brane-type  MMPs  (MT-MMPs)  are  cell  membrane-linked 
proteases with diverse functions. Yet again demonstrating the 
complexity of the MMP system, MT1-MMP (MMP-14) is 
also released into the circulation (�en et al. 2008). Strome- Strome-
lysins (MMP-3 and -10) and matrilysins (MMP-7 and -26) are 
broad-spectrum proteinases that also have important regula-
tory functions such as activation of other MMPs. 694  Acta Orthopaedica 2009; 80 (6): 693–703
While most MMPs are secreted into the extracellular space 
immediately  after  synthesis  as  proenzymes  (pro-MMP), 
some may also be stored within cells (e.g. MMP-9 in neu-
trophil granules), and others are bound to cell surface mem-
branes (e.g. MT1-MMP). The pro-MMPs are activated by 
proteolytic cleavage in the extracellular space, where MMP-
3 appears to be a key player by activating other MMPs in this 
manner (van Meurs et al. 1999, Dollery and Libby 2006). 
Baseline production of MMPs is low. Synthesis of MMPs 
is induced by a broad range of stimuli including cytokines 
(interleukin-1, -4, -6, and -10, and tumor necrosis factor-α), 
growth factors, EMMP�IN (extracellular MMP inducer) and 
cell-cell or cell-matrix interactions, which all signal through 
intracellular pathways such as the mitogen-activated protein 
kinase pathway (Kossakowska et al. 1999, Meller et al. 2000, 
Hidalgo and Eckhardt 2001, Corps et al. 2004, Gabison et 
al. 2005).  
The  composition  of  the  ECM  depends  on  the  balance 
between tissue formation and breakdown (Figure 1). Because 
the latter is mediated mostly by MMPs, strict regulation of 
MMP production and activity is an essential part of ECM 
homeostasis. This regulation takes place at the levels of gene 
Table 1. The MMP family. Compiled from Hidalgo and Eckhardt (2001), Chakraborti et al. (2003), Pavlaki and Zucker (2003), Visse and 
Nagase (2003), Illman et al. (2006), Nagase et al. (2006), Pearce and Shively (2006). Stromelysin 3 is grouped with “other MMPs” since the 
enzyme has different properties from other stromelysins. Among the collagenous substrates for collagenases, bold numbers for collagens 
indicate strongest enzymatic activity
Group   MMP Collagenous substrates Noncollagenous ECM substrates Nonstructural ECM component substrates
Collagenases
  Collagenase 1
  Collagenase 2
  
  Collagenase 3
MMP-1
MMP-8
MMP-13
collagens I, II, III, VII, VIII, 
X, XI, gelatins
collagens I, II, III, V, VII, 
VIII, X
collagens I, II, III, IV, V, 
VII, IX, X, gelatins
proteoglycans, fibronectin, entactin, 
laminin, tenascin, vitronectin
fibronectin, laminin, proteoglycans
proteoglycans, fibronectin, laminin, 
tenascin
α-1-antiprotease, pro-TNFα
ADAMTS-1, pro-MMP-8
fibrinogen, proMMP-9 and -13
Gelatinases
  Gelatinase A
  
  Gelatinase B
MMP-2
MMP-9
gelatins, collagens I, II, 
III, IV, VII, X
gelatins, collagens IV, V, 
VII, X, XI
laminin, elastin, fibronectin, proteo-
glycans
laminin, elastin, fibronectin, proteo-
glycans 
pro-MMPs -9 and -13, α-1-antiprotease, 
IGFBPs, IL-1β, TGFβ
α-1-antiprotease, CXCL5, IL-1β, TGFβ, 
plasminogen
Stromelysins
  Stromelysin 1
  
  Stromelysin 2
MMP-3
MMP-10
collagens III, IV, V, VII, IX, 
X, XI, gelatins
collagens I, III, IV, V, IX, 
X, gelatins
laminin, fibronectin, elastin, proteo-
glycans
laminins, proteoglycans
pro-MMPs, pro-TNFα, E-cadherin, L-
selectin, fibrinogen
pro-MMPs
Matrilysins
  Matrilysin 1
 
  Matrilysin 2
MMP-7
MMP-26
gelatins, collagens I and 
IV 
as above
laminin, elastin, fibronectin, proteo-
glycans, tenascin
as above
pro-MMPs, pro-α-defensin, pro-TNFα, 
E-cadherin
as above
Membrane-type 
(MT) MMPs
  MT1-MMP
 
  MT2-MMP
  MT3-MMP
  MT4-MMP
  MT5-MMP
  MT6-MMP
MMP-14
MMP-15
MMP-16
MMP-17
MMP-24
MMP-25
gelatin, collagens I, II, III
gelatins, collagen III
gelatin
proteoglycans, fibronectin, tenascin, 
fibrinogen
fibronectin 
fibronectin
Pro-MMP-2 and -13
Pro-MMP-2
Pro-MMP-2
Pro-MMP-2 
Other MMPs
  Stromelysin 3
  Metalloelastase
  RASI
 
  Enamelysin
   -
   -
   -  
  Epilysin
MMP-11
MMP-12
MMP-19
MMP-20
MMP-21
MMP-23
MMP-27
MMP-28
collagens, gelatins 
gelatin
fibronectin
elastin, proteoglycans 
components of basement mem-
branes
amelogenin
α-1-antiprotease, serpins
plasminogen
Pro-TGFβ
ADAMTS: a disintegrin and metalloproteinase with thrombospondin motifs; ECM: extracellular matrix; TGF: transforming growth factor; 
TNF: tumor necrosis factor; RASI: rheumatoid arthritis synovial inflammation; IGFBP: insulin growth factor binding protein; 
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transcription,  pro-MMP activation,  and  inhibition  of  active 
enzymes (Figure 2). 
There are 4 TIMPs, which reversibly inhibit all MMPs by 
1:1 interaction with the zinc-binding site (Hidalgo and Eck-
hardt 2001). TIMP-1, -2, and -4 are found in the tissues as well 
as in the circulation, while TIMP-3 is sequestered in the ECM 
(Baker et al. 2002). The specificity of TIMPs for individual 
MMPs is quite overlapping, although MT-MMPs appear to 
be resistant to TIMP-1 (Baker et al. 2002, Dollery and Libby 
2006). TIMPs have several functions besides MMP inhibition, 
such as their roles in regulation of angiogenesis and cellular 
proliferation  (Chirco  et  al.  2006).  Additional  endogenous 
inhibitors of MMPs include the soluble α-1-antitrypsin and 
α-2-macroglobulin (Nagase et al. 2006), as well as cell mem- (Nagase et al. 2006), as well as cell mem-
brane-linked MMP inhibitors (Baker et al. 2002). 
MMPs appear to have prominent roles in several diseases 
with a component of tissue destruction, such as osteoarthritis 
and rheumatoid arthritis (Bramono et al. 2004). It should be 
mentioned, however, that the view of MMPs as being solely 
tissue-degrading enzymes is somewhat oversimplified. This 
has been exemplified in a model of Porphyromonas gingiva-
lis-induced periodontitis, where MMP-8 knockout mice suf-
fered a more extensive alveolar bone loss than wild-type mice 
(Kuula et al. 2009). These findings may be explained by data 
showing that MMPs can exert anti-inflammatory actions, pos-
sibly by processing of anti-inflammatory cytokines and che-
mokines (Owen at al. 2004, Gueders et al. 2005). The variable 
roles of MMPs are further illustrated by data from a case study 
on patients with a phenotype of multicentric osteolysis with 
e.g. carpal and tarsal resorption, arthritis, and osteoporosis. 
These patients originated from consanguinous families, and 
were shown to have a complete absence of pro- and active 
MMP-2 in serum, explained by 2 specific mutations in the 
MMP-2 gene (Martignetti et al. 2001). This underscores the 
complex physiological and developmental roles of MMPs.
ADAMs and ADAMTS. Two other groups of proteases are 
related  to  the  MMPs.  ADAMs  are  cell  membrane-linked 
enzymes  with  proteolytic  and  cell  signaling  functions. 
ADAMTSs are secreted into the circulation and constitute a 
heterogenous family of proteases with both anabolic and cata-
bolic functions. 
“A disintegrin and metalloproteinase” (ADAM) and “ADAM 
with thrombospondin motifs” (ADAMTS) proteins belong to 
the  family  of  metalloproteinases.  Only  recently  discovered, 
their functions are only beginning to be unravelled. ADAMs 
are usually linked to the cell membrane while ADAMTS are 
secreted pericellularly and into the circulation. However, alter- However, alter-
nate splicing of the ADAM genes also gives rise to circulating 
forms of these proteins. There are at least 33 ADAMs, and their 
functions include pericellular proteolysis of other membrane-
bound proteins (e.g. growth factors in precursor state), cell sig-
naling, and cell adhesion (Mochizuki and Okada 2007). The 
19 known subtypes of ADAMTS are divided into 4 groups. 
The aggrecanases (ADAMTS-1, -4, -5, -8, -9, -15, and -20) 
can be roughly described as having proteoglycanolytic action, 
although there are other reported functions such as regulation of 
angiogenesis and degradation of other proteins for some of the 
group members. ADAMTS-2, -3, and -14 constitute the second 
group and they have anabolic function, acting as procollagen N-
propeptidases for collagen types I, II, and III. Their importance 
in physiology is illustrated by the finding of an ADAMTS-2 
mutation in Ehlers-Danlos syndrome type VII C (a condition 
with fragile skin, joint laxity, and hernias). Thirdly, ADAMTS-
13 cleaves the von Willebrand factor involved in coagulation, 
and mutations in this protein are coupled to thrombotic throm-
bocytopenic purpura. There is a fourth group of ADAMTS (-
6, -7, -10, -12, -16, -17, -18, and -19) with largely unknown 
function (Jones and �iley 2005). TIMP-3 is the main TIMP to 
have any inhibitory activity against some of the ADAMs and 
ADAMTS (Mochizuki and Okada 2007). 
Figure 1. Degradation of the extracellular matrix is principally mediated 
by MMPs, which are counterbalanced by TIMPs. Disturbances of this 
equilibrium may lead to disease processes of fibrotic nature (left) or 
degradative nature (right).
Figure 2. Simplified drawing of MMP regulation. MMP gene transcrip-
tion is generally induced by stimuli such as inflammatory cytokines, 
which signal via specific intracellular pathways. MMPs are produced 
as inactive pro-enzymes that are subsequently cleaved to become 
active enzymes. MMP-3 appears particularly important in this regard, 
since it is known to activate several of the MMPs. Plasmin is also an 
important activator of MMPs. TIMPs inhibit MMPs mainly at the active 
level. MAPK: mitogen-activated protein kinase.
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MMP inhibitors. There are several types of MMP inhibitors, 
including tetracycline antibiotics. If proven effective for any 
anti-MMP indication, these already approved drugs might be 
quickly be brought into clinical practice. 
There are several classes of pharmacological MMP inhibi-
tors. The most common mechanism of action is binding to the 
zinc site of the MMP enzyme, thereby blocking its activity. 
The tetracycline antibiotics have several important non-antibi-
otic mechanisms (Figure 3) (Tamargo et al. 1991, Amin et al. 
1996, Kloppenburg et al. 1996, Golub et al. 1998, Yrjanheikki 
et al. 1999, Lee et al. 2004, Sapadin and Fleischmajer 2006). 
Doxycycline is considered to be the most potent MMP inhibi-
tor among the tetracyclines, and shows a broad spectrum by 
inhibiting MMPs -1, -2, -7, -8, -9, -12, and -13, although activ-
ity against the entire MMP family has not been determined 
(Golub  et  al.  1998,  Peterson  2004).  Besides  zinc-binding, 
tetracyclines also inhibit MMPs at the gene expression level 
and by reducing activation via the inflammatory cascade and 
through reactive oxygen species. 
Chemically modified tetracyclines have been developed to 
avoid  unwanted  effects  on  the  endogenous  microbial  flora 
while  retaining  the  MMP-inhibitory  action.  Effects  on  the 
microbial flora can also be avoided by administering “low-
dose” doxycycline, i.e. 20 mg twice a day instead of the stan-
dard dose of 100 mg twice a day. In this way, doxycycline 
still retains its MMP-inhibitory efficacy (Emingil et al. 2004, 
O’Dell et al. 2006) but has no effect on the microbial flora of 
the vagina or the gut (Walker et al. 2005). 
Synthetic MMP inhibitors constitute a large heterogeneous 
group of compounds, which have been modified to increase 
inhibitory  potency  and  to  produce  increased  specificity 
against particular MMPs (Hu et al. 2007). Bisphosphonates, 
known inhibitors of osteoclastic bone resorption, also have 
potent MMP-inhibitory properties, probably through cation-
chelation of zinc (Hidalgo and Eckhardt 2001, Heikkila et al. 
2002). 
Proteinases in soft tissues
Tendon disease. Tendon degeneration and rupture is largely 
mediated  by  MMPs.  Inhibition  may  become  a  therapeutic 
alternative.
The typical histopathological finding in painful tendinopa-
thy is degeneration, i.e. disorganized ECM, variation in the 
density of tendon cells ranging from hyper- to hypocellular-
ity, and increase in vascularity (�iley 2004, 2008, �ees et al. 
2006). Several reports have indicated that excessive matrix 
degradation has a role in the etiopathogenesis of painful tendi-
nopathy and tendon rupture (Table 1) (�iley 2004, de Mos et 
al. 2007). One pilot study has also suggested that there is a 
systemic disturbance in the regulation of MMPs and TIMPs 
in tendon rupture (Pasternak et al. 2008b). The impact of sys-
temic factors is emphasized by a study showing an associa-
tion between variants of the MMP-3 gene and painful Achilles 
tendinopathy (�aleigh et al. 2009). Painful tendinopathy and 
tendon rupture are probably two somewhat distinct entities, 
since degeneration in ruptured tendons is generally painless 
but more severe than in painful tendinopathy (Tallon et al. 
2001) and there are differences in the expression of structural 
proteins and proteolytic enzymes (Corps et al. 2006, Jones et 
al. 2006), as well as genetic differences (Mokone et al. 2006, 
�aleigh et al. 2009). 
Enzyme inhibitors have not been subject to any extensive 
evaluation  in  the  treatment  of  tendinopathy.  2  small  trials 
with peritendinous injections of aprotinin, a general protease 
inhibitor, have been conducted and showed some benefit for 
patellar and Achilles tendinopathy (Magra and Maffulli 2005). 
Further support for its efficacy comes from a large case series 
on chronic tendinopathy (Orchard et al. 2008). However, in 
a small randomized trial on Achilles tendinopathy, treatment 
with aprotinin as an adjunct to eccentric training was not found 
to be better than placebo (Brown et al. 2006). 
Pain in tendinopathy might be mediated by the neurotrans-
mitter substance P (SP) (Alfredson 2005, Schubert et al. 2005). 
Interestingly, SP is capable of regulating the gene expression 
of MMPs and TIMPs in fibroblasts (Cury et al. 2008), which 
may link SP to the altered regulation profile of MMPs and 
TIMPs observed in tendinopathy. SP is also involved in repair 
processes  and,  when  administered  exogenously,  appears  to 
enhance proliferation of fibroblasts and tendon healing (Ack- (Ack-
ermann et al. 2003, Burssens et al. 2005, Steyaert et al. 2006). 
Furthermore,  patients  who  develop  shoulder  stiffness  after 
arthroscopic rotator cuff repair have been found to have mark-
edly elevated plasma SP levels as compared to patients with a 
good postoperative outcome (Franceschi et al. 2008). 
The Achilles tendon has served as the model tendinopathy 
for etiopathologic studies, and will probably serve as a model 
tendinopathy for treatment studies. However, the molecular 
profiles of tendinopathy in other regions should be determined 
Figure 3. Mechanisms of action of tetracyclines. Tetracyclines have 
several non-antimicrobial effects. The ability of these drugs to inhibit 
matrix metalloproteinases is well established. Based on this mecha-
nism, tetracyclines have shown clinical effects on rheumatoid arthritis 
and periodontitis. Doxycycline and minocycline are the two tetracy-
clines that have been studied most extensively. TNF: tumor necrosis 
factor; IL: interleukin; NO: nitric oxide; PG: prostaglandin.
Tetracyclines inhibit:
Bacteria
Inflammation
Tissue-
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Protein synthesis 
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since supraspinatus tendinopathy, for example,  may be a dis-
tinct entity as compared to Achilles tendon disease (Lo et al. 
2004). Thus, detailed molecular studies are required in order 
to be able to tailor specific mechanism-based therapy. 
Tendon healing. General inhibition of MMPs impairs tendon 
healing, but more selective treatment might possibly have a 
positive effect. Sutures coated with MMP inhibitors have a 
better grip.
Only a few studies have dealt with the role of MMPs in 
tendon healing. Based on m�NA data from unloaded heal- Based on m�NA data from unloaded heal-
ing rat flexor tendons, it has been suggested that MMP-9 and 
MMP-13 participate only in tissue degradation during the early 
phase of healing, while MMP-2, -3, and -14 participate both in 
tissue degradation and in later remodeling (Oshiro et al. 2003). 
These data must be confirmed—especially in view of the large 
differences observed in mechanical properties and expression 
of growth factor genes, depending on the loading status of the 
tendon during healing (Virchenko and Aspenberg 2006, Elias-
son et al. 2008). An experimental study showed that systemic 
treatment with the MMP inhibitor doxycycline led to weaken-
ing of rat Achilles tendons during healing, which suggests that 
MMPs are important for tendon healing (Pasternak et al. 2006). 
However, the results do not rule out the possibility that MMP 
inhibitors could be used to enhance tendon healing, since stud-
ies of specific MMPs that act during tendon healing may iden-
tify those that are deleterious to healing, thus allowing treat-
ment with inhibitors specific for certain subspecies of MMPs. 
�esults from a pilot study suggest that the target MMP may be 
MMP-7, since there was a strong inverse correlation between 
levels of this proteinase and tendon strength during healing in 
humans (Pasternak et al. 2008b). MMP-13 could be another 
target; it has been implicated in tendon degradation caused by 
stress-deprivation (Arnoczky et al. 2007) and its expression is 
strongly upregulated in rotator cuff rupture (Lo et al. 2004). 
Several experimental studies have shown that the mechani-
cal properties of tendon can be manipulated by MMP inhibi-
tors. An ex vivo rat tail tendon model showed that weaken-
ing of tendon induced by unloading could be inhibited by the 
MMP inhibitors GM 6001 and doxycycline (Arnoczky et al. 
2007). Furthermore, a rabbit model of anterior cruciate liga-
ment reconstruction showed that the endogenous MMP inhibi-
tor  α-2-macroglobulin,  injected  intra-articularly,  improved 
mechanical and histological characteristics of tendon to bone 
healing (Demirag et al. 2005). 
Experimental studies have shown that the strength of the 
suture construct in tendons becomes transiently reduced in the 
immediate postoperative period after surgical repair of tendon 
rupture (Wada et al. 2001, Yildirim et al. 2006). A degradative 
process, mediated by MMPs, is thought to occur in the direct 
vicinity of the sutures, leading to weakening of tendon tissue 
around the suture (McDowell et al. 2002). This is thought to 
facilitate the suture to cut through the tendon when exposed 
to tensile stress, i.e. during mobilization. Inhibition of MMPs 
could thus help to improve tendon suture-holding capacity. 
Based on this idea, it has been shown that doxycycline-coated 
sutures can improve early tendon suture-holding capacity in a 
rat model (Pasternak et al. 2007). 
Frozen shoulder. �educed MMP activity may be involved in 
the pathogenesis of frozen shoulder.
In the late 1990s, several cancer trials with MMP inhibi-
tors  were  conducted.  In  one  study,  frozen  shoulder  and/or 
Dupuytren’s-like contracture was reported in 6 of 12 gastric 
Table 2. mRNA expression and enzyme activity (or levels of active enzyme) of MMPs, TIMPs, ADAM, and ADAMTS in 
human tendon disease. Only proteins that showed statistically significant differences between groups are shown. Note 
that there are some contrasting results due to differences between studies. Data from Riley et al. (2002), Alfredson et 
al. (2003), Lo et al. (2004), Voloshin et al. (2005), Jones et al. (2006), de Mos et al. (2007), Corps et al. (2008), Karousou 
et al. (2008), and de Mos et al. (2009) 
Elevated Decreased
Painful Achilles tendinopathy 
compared to control
Gene expression MMP-2, -11, -13, -16, -23
ADAM-12
ADAMTS-2, -3
MMP-3, -10, -12, -27
TIMP-3
ADAMTS-5
Activity MMP-3 n.a.
Ruptured Achilles tendon 
compared to control
Gene expression MMP-1, -2, -9, -11, -14, -17, -19, -25
TIMP-1
ADAM-8, -12
ADAMTS-4
MMP-3, -7, -24, -28
TIMP-2, -3, -4
ADAMTS-7, -13
Activity MMP-2 and 9
ADAMTS-4
n.a.
Ruptured rotator cuff 
compared to control
Gene expression MMP-13 MMP-3
TIMP-2, -3, -4
Activity MMP-1, -9, -13 MMP-2
n.a.: not applicable.698  Acta Orthopaedica 2009; 80 (6): 693–703
cancer patients treated with the MMP inhibitor marimastat 
(Hutchinson et al. 1998). Musculoskeletal side effects were 
later confirmed by reports of adverse effects from large trials 
evaluating MMP inhibitors for various indications. The group 
of side effects included frozen shoulder, Dupuytren’s-like con-
tracture, and arthralgias, and it was named the musculoskeletal 
syndrome (MSS). Although the exact mechanism is unknown, 
MSS is attributed either to the inhibition of too wide a spec-
trum of MMPs, or to unavoidable side effects of inhibiting the 
specifically targeted MMPs (Peterson 2004). Side effects from 
MMP inhibitors appear to be dose-dependent and develop only 
in patients on long-term therapy. The latter indicates that MSS 
will not be a problem for potential short-term indications, e.g. 
perioperative treatment. Furthermore, MSS is not a feature of 
every MMP inhibitor and has not been reported with tetracy-
clines. In addition, subspecies-selective MMP inhibitors may 
not have these side effects.
A non-quantitative gene expression study on frozen shoul-
der tissue showed an absence of MMP-14 as well as reduced 
expression of MMP-1, indicating that reduced collagenolysis 
may have a role in the pathogenesis of this disease (Bunker et 
al. 2000). Further studies using quantitative PC� and protein 
detection techniques will be needed in order to obtain a better 
understanding of this disease. Future therapy could possibly 
be directed at inhibition of the TIMPs, preferably by a local 
drug delivery approach.
Dupuytren’s disease. This disease has a complex regula-
tion profile of metalloproteinases and inhibitors. TIMP-1 may 
be the most important. Local injection of MMPs has shown 
therapeutic promise.
Dupuytren’s disease of the hand, which is common in north-
ern Europe, is a fibroproliferative disease of the palmar fascia. 
Myofibroblasts are responsible for contraction of the tissue, 
leading to hand dysfunction. Nodules in Dupuytren’s disease 
represent  active  disease  with  myofibroblast  proliferation, 
while cords are typical of late-stage disease. A comprehensive 
gene expression profiling of MMPs, TIMPs, and ADAMTS 
using tissue samples from nodules and cords of patients with 
Dupuytren’s disease and control palmar fascia samples from 
patients with carpal tunnel disease revealed a complex regula-
tion profile with distinctive patterns for active and late-stage 
disease (Table 3) (Johnston et al. 2007). Based on these find-
ings, the authors suggested that contraction and fibrosis in 
Dupuytren’s  disease  may  result  from  several  mechanisms 
including ADAMTS-14-mediated promotion of collagen syn-
thesis, TIMP-1 inhibition of collagenolytic activity, and MMP-
14-mediated pericellular collegenolysis, allowing contraction. 
Interestingly, levels of some of the MMPs and ADAMTS were 
found to show a correlation with recurrence more than a year 
later (Johnston et al. 2008), suggesting their possible clinical 
use as predictive markers. In addition, it was shown that the 
broad-spectrum MMP inhibitor GM6001 (ilomastat) reduced 
Dupuytren’s disease fibroblast-mediated contraction in an in 
vitro model (Townley et al. 2008). 
One further study has highlighted the key role of TIMP-1 
in the pathogenesis of fibrotic changes in Dupuytren’s dis-
ease (Ulrich et al. 2003). The investigators showed elevation 
of TIMP-1 in the serum of patients with active Dupuytren’s 
disease  as  compared  to  carpal  tunnel  syndrome  controls, 
whereas the levels were similar between patients with inac-
tive late-stage disease and controls. There was also a shift in 
the systemic MMP-TIMP balance. Detection of these changes 
in blood samples illustrates the important role of TIMP-1. 
In view of the strong hereditary component and a predilec-
tion for men in Dupuytren’s disease, it is interesting to note 
that TIMP-1 is located on the X-chromosome. One approach 
to address this issue would be to investigate whether single 
nucleotide polymorphisms and other genetic variation in, for 
example TIMP-1, might explain some of the familial predis-
position to Dupuytren’s disease.  
In  view  of  TIMP-1  being  an  important  mediator  in  the 
pathogenesis of Dupuytren’s disease, pharmacological target-
Table 3. mRNA expression of MMPs, ADAMTS, and TIMPs in nodule tissue (active disease) and cord tissue (end-stage 
disease) from patients with Dupuytren’s disease (n = 19) as compared to control palmar fascia from patients with carpal 
tunnel syndrome (n = 19). Data from Johnston et al. (2007). Only proteins that showed statistically significant differences 
between groups are shown. 
Elevated Decreased
Dupuytren’s nodule 
compared to control
MMP-1, -2, -7, -11, -13, -14, -15, -16, 
-17, -19, -21
ADAMTS-2, -3, -4, -5, -9, -14, -16, -18
TIMP-1
MMP-3
ADAMTS-1, -6, -8, -19, -20
TIMP-2, -3, -4
Dupuytren’s cord 
compared to control
MMP-2, -7, -11, -13, -16
ADAMTS-3, -12, -18
MMP-3
Dupuytren’s nodule 
compared to cord
MMP-2, -11, -13, -14, -15, -16, -17, 
-19, -28 
ADAMTS-2, -4, -5, -12, -14
TIMP-1
MMP-3, -8
ADAMTS-1, -6, -8
TIMP-2, -4Acta Orthopaedica 2009; 80 (6): 693–703  699
ing of this protein has been suggested as a possible therapy 
(Johnston et al. 2007). In another approach to non-surgical 
therapy, the effect of collagenase injections has been investi-
gated in a double-blind randomized placebo-controlled trial of 
35 patients with Dupuytren’s disease (Badalamente and Hurst 
2007). Improvement was seen in 21 of 23 patients treated with 
up to 3 injections of collagenase, as compared to none of the 
patients treated with placebo. Although there are safety issues 
because of frequent adverse events, these results are promis-
ing and merit further investigation. 
Disorders of the spine. Metalloproteinases are dysregulated 
in disc disease, and idiopathic scoliosis, ankylosing spondyli-
tis, and disc disease have been connected to genetic variants 
of MMPs.
Degeneration of the anulus fibrosus of intervertebral discs, 
leading to disc herniation and sciatic pain, is thought to be 
mediated (at least in part) by MMP-1 and -3 (Goupille et al. 
1998). Furthermore, a recent study has shown elevation of 
ADAMTS-1,  -4,  -5,  and  -15  in  degenerated  intervertebral 
discs, with the levels of ADAMTS-4, -5, and -15 increasing 
with increasing degree of degeneration (Pockert et al. 2009). 
Degeneration  of  intervertebral  discs  appears  to  have  a 
strong genetic component, as shown by epidemiological stud-
ies (Ala-Kokko 2002). This may be partly explained by MMP 
gene variants. A single nucleotide polymorphism (C to T) in 
the promotor region of the MMP-2 gene results in reduced 
transcription. Patients with lumbar disc degeneration have a 
higher rate of homozygosity for the CC genotype (Dong et al. 
2007). Furthermore, patients with the the CC genotype have 
more severe disc degeneration than patients with CT and TT 
genotypes. This suggests that patients prone to disc degen-
eration have a tendency to have higher transcription of the 
MMP-2 gene and that among patients with disc degeneration, 
those with higher transcription of the MMP-2 gene have more 
severe disease. Whether or not the CC genotype is associated 
with higher tissue and systemic levels of MMP-2 is, however, 
unknown.
There is a highly variable region within the promoter region 
of the MMP-3 gene, the so-called 5A/6A polymorphism. One 
allele has a run of 6 adenosines (6A) and the variant allele has 
a run of 5 adenosines (5A). It has been reported that the 5A 
allele has twice as much promoter activity as the 6A allele. 
About half of the population carries this allele. In a radio-
graphic  study  of  volunteers,  this  genotype  was  associated 
with intervertebral disc degeneration in elderly, but not young, 
patients (Takahashi et al. 2001). In a small study, Aulisa et al. 
(2007) reported an association between adolescent idiopathic 
scoliosis and the 5A/6A MMP-3 promoter polymorphism. The 
rate of having a homozygous genotype for the 5A allele of the 
MMP-3 promoter was found to be 3 times higher in scoliotic 
patients (30%) than in healthy controls (11%).  
MMP-3 has also been implicated in ankylosing spondyli-
tis. Serum MMP-3 levels were found to be twice as high in 
ankylosing spondylitis patients than in controls, and showed 
a positive correlation with disease activity (Chen et al. 2006). 
In addition, serum MMP-3 was found to be an independent 
predictor of radiographic progression 2 years later, particu-
larly in patients with pre-existing radiographic damage (Mak- (Mak-
symowych et al. 2007). Circulating MMP-3 levels were also 
reduced by TNF-α-blocker treatment in ankylosing spondyli-
tis, and there was a correlation between changes in MMP-3 
and  changes  in  disease  activity  during  treatment  (Maksy-
mowych et al. 2008).
Fracture  healing.  Fracture  non-union  is  associated  with 
altered levels of serum MMPs. Variation in the healing of 
other tissues appears to be related to MMPs. This may also 
be the case for bone fractures, indicating that there may be 
therapeutic possibilities. 
Patients who develop non-union of long bone fractures have 
been found to have higher levels of  pro-MMP-1 and MMP-8, 
and lower TIMP-1 in serum during postoperative monitoring 
than patients who heal normally (Henle et al. 2005). The same 
research group also showed suppression of serum TGF-β in 
patients who developed non-union (Zimmermann et al. 2005). 
This suggests that there may be a possibility of monitoring and 
predicting the outcome of healing using blood samples. In fact, 
there have been a few studies in other fields of research that 
have shown associations between MMP levels and outcome 
of tissue healing. Preoperative MMP-9 levels in nasal secre-
tions were found to show an inverse correlation with quality of 
healing after sinus surgery (Watelet et al. 2004), while MMP-9 
in wound fluid obtained at 24 hours after inguinal hernia sur-
gery showed an inverse correlation with collagen deposition 
at 10 days (Agren et al. 1998). MMP-1, -2, and -9 levels in 
peroperative intestinal biopsies were elevated in patients who 
developed anastomotic wound failure after colorectal resec-
tion (Stumpf et al. 2005). MMP inhibitors have been shown 
to improve healing of intestinal and cutaneous wounds (Witte 
et al. 1998, Syk et al. 2001, Pasternak et al. 2008a). Future 
experimental studies will show whether there is any effect of 
MMP inhibitors (general and selective) on fracture healing.
Prosthetic loosening. Genetic variants of MMP regulation 
are related to increased risk of loosening.
The  causes  of  aseptic  loosening  of  hip  prostheses  have 
been debated extensively (Sundfeldt et al. 2006). Studies of 
the implant interface membrane tissue have shown evidence 
of MMP-mediated collagen breakdown (Takagi 1996) and the 
extracellular matrix metalloproteinase inducer (EMMP�IN), 
which upregulates several MMPs, has been found at elevated 
levels around loosened implants (Li et al. 1999). Expression 
of several MMPs appears to be upregulated in macrophages in 
vitro in response to titanium and PMMA particles (Nakashima 
et al. 1998). These data suggest the possibility of pharmaco-
logical intervention in patients who (begin to) develop asep-
tic loosening. Intriguingly, in vitro bone resorption by cells 
obtained from the interface membrane of patients with aseptic 
loosening of hip prostheses can be inhibited by doxycycline 
(Ong and Taylor 2003). 700  Acta Orthopaedica 2009; 80 (6): 693–703
Finally, a single nucleotide polymorphism (SNP) in the pro-
moter region of the MMP-1 gene has been found to be asso-
ciated with aseptic loosening of hip prostheses (Malik et al. 
2007). Another, smaller study found an association between a 
different SNP in the MMP-1 gene promoter region and asep-
tic loosing of hip prostheses (Godoy-Santos et al. 2009). This 
SNP increases the activity of the MMP-1 gene (�utter et al. 
1998), and therefore patients with this gene variant may have 
elevated MMP-1 production that results in excessive tissue 
damage. Further investigation of this SNP may provide a way 
of identifying patients at risk of prosthetic loosening, even 
before surgery.
Joint diseases
Rheumatoid arthritis. Because MMPs mediate joint destruc- Because MMPs mediate joint destruc-
tion, MMP inhibitors are now used as therapeutics for mild 
rheumatoid arthritis.
MMPs  have  been  established  as  major  mediators  of  the 
destruction of joint cartilage and bone in rheumatoid arthritis 
(�A) (Tchetverikov et al. 2004, �engel et al. 2007) and this 
knowledge is now about to be applied in the clinic. Circulating 
MMP-1 and -3 have been suggested to be promising markers 
of disease severity in �A (Green et al. 2003). One study in 
which several biomarkers were evaluated showed that baseline 
serum MMP-3 is a reliable predictor of radiographic progres-
sion of �A 2 years later (Young-Min et al. 2007). A functional 
polymorphism in the MMP-3 gene promoter, associated with 
elevated serum levels of MMP-3, has been linked to radio-
graphic progression of �A in European but not in Japanese 
patients (Constantin et al. 2002, Mattey et al. 2004, Tsukahara 
et al. 2008). 
Further evidence for the implication of MMPs in �A has 
come  from  treatment  studies.  6  months  of  treatment  with 
methotrexate  of  patients  with  newly  diagnosed  �A  led  to 
reduced serum levels of MMP-1, -9, -13, and TIMP-1 (Fie-
dorczyk et al. 2006). In another study, lefluonomide and meth-
otrexate treatment both led to a decrease in activated MMPs in 
serum of patients with �A (Tchetverikov et al. 2008). Cortico- (Tchetverikov et al. 2008). Cortico-
steroid injections into the knee joint of patients with active �A 
synovitis induced suppression of serum MMP-3, but not of the 
MMP-1/TIMP-1 complex (Weitoft et al. 2008).
Tetracycline  MMP  inhibitors  have  been  evaluated  in  a 
few randomized controlled �A trials. A study involving 66 
patients with early seropositive �A evaluated doxycycline as 
an adjunct therapy to methotrexate. At the 2-year follow-up, 
the doxycycline-methotrexate combination had improved the 
main outcome variable (American College of �heumatology; 
AC� 50%) as compared to methotrexate alone (O’Dell et al. 
2006). Importantly, the positive effects were similar between 
the standard dose of 100 mg twice daily and 20 mg twice daily, 
corroborating the concept of low-dose doxycycline, i.e. that 
the mechanism of action is dependent on the MMP-inhibitory 
and anti-inflammatory actions of doxycycline rather than any 
possible antimicrobial effects. Benefit of another tetracycline 
MMP inhibitor, minocycline, has also been demonstrated in 
a randomized trial (O’Dell et al. 2001). There have, however, 
also been studies that showed no effects of tetracyclines on 
symptoms and progression of �A (van der Laan et al. 2001). 
Minocycline is currently included in the AC� guidelines as an 
alternative in the treatment of �A of short duration, with low 
disease activity and absence of poor prognostic features (Saag 
et al. 2008). There have been no published trials evaluating 
synthetic MMP inhibitors in �A. Because of the important 
pathophysiological roles of, for example, MMP-3 and -13 in 
�A, trials with selective MMP inhibitors are eagerly awaited. 
When approaching the clinical use of MMP as markers of, 
for example, disease activity, there will be a need for stand-
ardization of sampling procedures and types of assay, as vari-
ations in levels between serum and plasma and several other 
factors are important for the interpretation of the results (Man-
nello 2008). 
Osteoarthritis. MMP-3 levels appear to be related to prog- MMP-3 levels appear to be related to prog-
nosis. MMP inhibitor therapy has already been tried, with 
mixed results.
Gene expression for several of the proteolytic MMP and 
ADAMTS  enzymes  is  upregulated  in  cartilage  and  syn-
ovium in patients with osteoarthritis (OA) (Davidson et al. 
2006). Furthermore, there is downregulation of TIMP-1 and 
-4  expression  in  OA  cartilage,  suggesting  an  altered  bal-
ance favoring proteolysis. MMP-13, the collagenase with the 
strongest activity against type II collagen, is thought to be one 
of the key metalloproteinases in OA-associated joint destruc-
tion (Takaishi et al. 2008). 
MMP-3 has been evaluated as a prognostic tool in predic-
tion of the disease course in OA. Patients with plasma MMP-3 
levels in the upper tertile of the baseline distribution have been 
found to be more likely to suffer progression of OA over a 30-
month period than patients in the lower tertile (odds ratio: 4) 
(Lohmander et al. 2005).
�andomized trials have shown conflicting results of MMP 
inhibitor treatment in OA. Doxycycline has been found to 
have positive effects on radiographic progression but had no 
effect on joint pain (Brandt et al. 2005), while PG-116800, a 
broad-spectrum synthetic MMP inhibitor, showed no effect in 
a large study (Krzeski et al. 2007).
Septic, Borrelia-induced, and reactive arthritis. In several 
types of arthritis, MMP inhibition may reduce joint destruc-
tion. 
Septic arthritis often leads to rapid destruction of joint car-
tilage and periarticular bone. Synovial fibroblasts exposed to 
Staphylococcus aureus show strong upregulation of several 
MMPs (Kanangat et al. 2006). MMP-7-deficient mice devel-
oped less joint destruction in a model of septic arthritis (Gjerts-
son et al. 2005). In another animal model, treatment with a 
bisphophonate together with antibiotics led to reduced bone 
resorption (Verdrengh et al. 2007). Although bisphosphonates 
inhibit resorption directly, it is possible that some of the effects 
may also have been mediated by the MMP-inhibitory action of Acta Orthopaedica 2009; 80 (6): 693–703  701
the bisphophonate, because addition of corticosteroids to anti-
biotics and alendronate further improved some of the param-
eters under study. Furthermore, dexamethasone was shown to 
reduce duration of symptoms and long-term joint dysfunction 
in a randomized placebo-controlled study of 123 children with 
septic arthritis (Odio et al. 2003). Being strongly anti-inflam-
matory and known to inhibit several mediators, including, for 
example,  MMP-9  (Liu  et  al.  2008),  corticosteroids  require 
further study in septic arthritis. Although not uncontroversial, 
if effective, they could revolutionize the treatment of septic 
arthritis. 
Investigation of Borrelia arthritis has shown the presence of 
several MMPs and the aggrecanase ADAMTS-4 in the joint 
fluid of arthritis patients and in cartilage explants infected 
with Borrelia (Hu et al. 2001, Behera et al. 2006). These stud-
ies also showed that the MMP inhibitor batimastat reduces 
glucosaminoglycan  and  collagen  degradation  in  cartilage 
explants infected with Borrelia. Based on its antimicrobial 
effect, doxycycline is already in widespread clinical use for 
Borrelia arthritis. In view of the MMP-inhibitory action of 
doxycycline, it would be interesting to compare the joint-spar-
ing effect of doxycycline with that of other antibiotics in use 
for Borrelia arthritis. In reactive arthritis, however, randomized 
controlled trials have so far not shown any positive effects of 
tetracyclines (Lauhio et al. 1991, Smieja et al. 2001).
Conclusion
MMPs are important mediators of connective tissue break-
down. They constitute promising pharmacological targets for 
clinical applications in orthopedics, rheumatology, and pri-
mary care. Furthermore, MMPs and related proteins may have 
a diagnostic role in prediction of the outcome of disease proc-
esses and healing.  
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